Abiomed, Inc.

Headquarters: Danvers, MA, United States

Founded: 1981

Employees: 1,725

CEO: Mr. Michael R. Minogue

show_chart NASDAQ: ABMD +0.12%

Market Cap

$14.79 Billion

USD as of April 1, 2022

history Market Cap History

Abiomed, Inc. market capitalization over time

Evolution of Abiomed, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Abiomed, Inc.

Detailed Description

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Wikipedia Introduction

Abiomed is a publicly-traded medical devices company that develops and manufactures external and implantable circulatory support devices. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year.

Source: Wikipedia, retrieved on Feb. 18, 2021, 3:52 p.m.

Stocks & Indices

Abiomed, Inc. has the following listings and related stock indices.


Stock: BMV: ABMD

Stock: Bovespa: A1BM34

Stock: FSX: AIO

Product & Services

Cardiovascular medical implant devices

Key People

Michael R. Minogue, CEO Thorston Siess, CTO Chuck Simonton, CMO Dr. David M. Weber, COO Andrew Greenfield, CCO


Revenue: US$840.88 million (2020)

Operating income: US$249.22 million (2020)

Net income: US$203.01 million (2020)

Total assets: US$1.2 billion (2020)

Total equity: US$1.06 billion (2020)



22 Cherry Hill Drive

Danvers, MA 01923

United States

Phone: 978 646 1400

Fax: 978 777 8411